Federal Register Notice: FDA has determined the regulatory review period for Nihon Nohyaku Co.’s Luzu is 2,242 days for extending a patent which claims the human drug product. Luzu is indicated for topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Tricophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older. To view this notice, click here.
